Blog

The latest thoughts from Medicines Law & Policy partners.

Imagine if health and trade ministers would meet in one room this week

A earlier version of this commentary was published on 28 November 2021 by Barron's. This is a time of missed opportunities. This week, trade ministers...

World Trade Organization Members Embark on Review of the TRIPS Agreement

The World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council will meet on 10-11 July. On the agenda is the review...

Medicines Excitement in the Netherlands – New Health Minister announces firm action on...

The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced...

EU Review of Pharmaceutical Incentives: Recommendations for Change

In 2016, the European Council decided it was time for a review of the incentives that the EU provides to companies that develop new...

Pharmaceutical Accountability Foundation meets AbbVie in court, looking to advance its pricing case

“The value of a human life is infinite, but unfortunately our healthcare budget is not,” said former Dutch Health Minister Bruno Bruins, quoted by...

Cancer Drug Pricing on the World Health Organization’s Executive Board Agenda

On Thursday 24 January, the World Health Organization’s 144th Executive Board meeting will kick off in Geneva. One of the agenda items is access...

TRIPS Council to discuss IP and the public interest in the context of Covid-19

The search for new treatments and vaccines needed to respond to the Covid-19 outbreak has laid bare some key issues around intellectual property (IP)...

Time for new pharmaceutical-innovation models

The pharmaceutical industry is one of the most profitable on earth, expected to be worth $1.4 trillion by the end of 2020. Last year,...

Humiragate: AbbVie’s desperate attempts to keep its monopoly

A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...

Fair Medicines Pricing requires addressing monopolies and increasing transparency in pharmaceutical markets

The 4th WHO Fair Pricing Forum took place from 6 - 8 February 2024. Ellen 't Hoen spoke at the opening plenary. Below are...